Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ciforadenant |
Synonyms | |
Therapy Description |
Ciforadenant (CPI-444) is an antagonist of the adenosine receptor A2aR, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (PMID: 29923026, PMID: 30131376). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ciforadenant | CPI-444|CPI 444|CPI444|V81444||V-81444 | Adenosine Targeting 23 | Ciforadenant (CPI-444) is an antagonist of the adenosine receptor A2aR, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (PMID: 29923026, PMID: 30131376). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04280328 | Phase I | Ciforadenant + Daratumumab Ciforadenant | Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma | Completed | USA | 0 |
NCT02655822 | Phase I | Atezolizumab + Ciforadenant Ciforadenant | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Completed | USA | CAN | AUS | 0 |